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Abstract
Background: Four of five Plasmodium species infecting humans are present in Madagascar. Plasmodium vivax
remains the second most prevalent species, but is understudied. No data is available on its susceptibility to
sulphadoxine-pyrimethamine, the drug recommended for intermittent preventive treatment during pregnancy. In
this study, the prevalence of P. vivax infection and the polymorphisms in the pvdhfr and pvdhps genes were
investigated. The correlation between these polymorphisms and clinical and parasitological responses was also
investigated in P. vivax-infected patients.
Methods:  Plasmodium vivax clinical isolates were collected in eight sentinel sites from the four major
epidemiological areas for malaria across Madagascar in 2006/2007. Pvdhfr and pvdhps genes were sequenced for
polymorphism analysis. The therapeutic efficacy of SP in P. vivax infections was assessed in Tsiroanomandidy, in
the foothill of the central highlands. An intention-to-treat analysis of treatment outcome was carried out.
Results: A total of 159 P. vivax samples were sequenced in the pvdhfr/pvdhps genes. Mutant-types in pvdhfr gene
were found in 71% of samples, and in pvdhps gene in 16% of samples. Six non-synonymous mutations were
identified in pvdhfr, including two novel mutations at codons 21 and 130. For pvdhps, beside the known mutation
at codon 383, a new one was found at codon 422. For the two genes, different combinations were ranged from
wild-type to quadruple mutant-type. Among the 16 patients enrolled in the sulphadoxine-pyrimethamine clinical
trial (28 days of follow-up) and after adjustment by genotyping, 3 (19%, 95% CI: 5%–43%) of them were classified
as treatment failure and were pvdhfr 58R/117N double mutant carriers with or without the pvdhps  383G
mutation.
Conclusion: This study highlights (i) that genotyping in the pvdhfr and pvdhps genes remains a useful tool to
monitor the emergence and the spread of P. vivax sulphadoxine-pyrimethamine resistant in order to improve the
national antimalarial drug policy, (ii) the issue of using sulphadoxine-pyrimethamine as a monotherapy for
intermittent preventive treatment of pregnant women or children.
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Background
Plasmodium vivax remains the second most common cause
of malaria in the world, infecting more than 80 million
people annually. It is the most geographically widespread
malaria parasite and it is found throughout South and
Central America, Asia, the Middle East and parts of Africa
[1].
Malaria is endemic throughout Madagascar, except in
highland regions above 1,500 m. Plasmodium falciparum is
the dominant malaria species, but P. vivax and Plasmodium
malariae have an increased prevalence in the foothills of
the central highlands [2,3]. With over one million sus-
pected cases reported in 2005, malaria remains one of the
leading cause of morbidity and mortality in the country
[4-6]. Although P. vivax causes less mortality than P. falci-
parum, it is responsible for significant morbidity and eco-
nomic loss.
For the past 50 years, chloroquine was used as the first line
treatment for malaria in Madagascar, with SP the second
line treatment choice. In 2005, the National Malaria Con-
trol Programme (NMCP) decided to revise its treatment
policy, replacing CQ by artemisinin-based combination
therapy (AQ+AS, a combination of artesunate plus amo-
diaquine) and recommending SP for intermittent preven-
tive treatment for pregnant women (IPTp) [7]. Some
studies in vivo [8] and in vitro [9-11] have investigated the
susceptibility of P. falciparum to this drug, but no data
concerning the susceptibility of P. vivax to SP is available.
Molecular and epidemiological studies have clearly
shown that, as for P. falciparum, the major mechanism of
resistance to SP involves specific point mutations in the
dhfr (dihydrofolate reductase) and dhps (dihydropteroate
synthase) genes of the parasite. In total, 20 non-synony-
mous mutations have already been described in the pvdhfr
gene [12]. Some of these mutations (at codons 57, 58, 61,
117 and 173) are involved in resistance to pyrimethamine
[12]. Five mutations have already been identified in the
pvdhps gene, at codons 382, 383, 512, 553 and 585, corre-
sponding to positions 436, 437, 540, 581 and 613 of the
homologous gene in P. falciparum. No data is available
about polymorphism in the pvdhfr and pvdhps genes of
malaria parasites from Madagascar. Only one pvdhfr gene
mutation, at codon 33, has been identified in some iso-
lates (four of nine from Madagascar and the Comoro
Islands), but this mutation has not been reported to be
associated with clinical resistance or resistance in vitro
[13,14].
Since, it is difficult to monitor the susceptibility of P. vivax
to antimalarial drugs by in vitro tests [15], molecular
markers of drug resistance are useful tools for mapping
the current and changing pattern of SP-resistant P. vivax
isolates. The aims of this study were: (i) to assess polymor-
phisms in the pvdhfr and pvdhps genes, using 159 P. vivax
samples, and (ii) to correlate pvdhfr/pvdhps patterns with
clinical and parasitological responses in P. vivax-infected
patients.
Methods
Collection of clinical isolates of P. vivax
Plasmodium vivax clinical isolates were collected in 2006/
2007 from individuals seeking treatment for malaria at
government health facilities located in areas correspond-
ing to the four epidemiological strata for malaria across
Madagascar: Ejeda and Ihosy in the South (epidemic-
prone area), Tsiroanomandidy and Moramanga/Saharevo
in the foothills of the Central Highlands (low-level
endemic area), Maevatanana and Miandrivazo in the West
(seasonal and endemic area) and Farafangana and
Andapa in the East (periannual endemic area). All
patients with fever or a history of fever in the 48 h before
their arrival at the health centre were screened with the
rapid diagnostic test (RDT), which is based on the detec-
tion of Plasmodium-specific lactate dehydrogenase
(pLDH) (OptiMAL-IT™, DiaMed AG©, Cressier sur Morat,
Switzerland). Giemsa-stained thin and thick blood films
were prepared for each patient with a positive RDT result.
The various species of Plasmodium were identified and par-
asitaemia was assessed by a skilled microscopist. Once
informed consent had been obtained from all adults and
from at least one parent for minors, blood was collected
on filter paper. Patients with positive microscopy results
were promptly treated according to National Malaria Pol-
icy.
SP efficacy
The therapeutic efficacy of the sulphadoxine-pyrimeth-
amine was assessed in P. vivax infections in 2006 in
Tsiroanomandidy. The clinical protocol was reviewed and
approved by the National Ethics Committee of the Minis-
try of Health and Family Planning of Madagascar (N°
102-SANPF-2006). Patients with blood smear confirmed
P. vivax infection were enrolled based on the inclusion cri-
teria given in WHO guidelines (2001) [16]. Informed con-
sent was obtained from all adults and from at least one
parent for minors and patients were treated with the
standard SP regimen (25 mg/kg sulphadoxine and 1.25
mg/kg pyrimethamine as a single dose on day 0) and fol-
lowed for 28 days. Each patient was weighed and medical
history (including previous antimalarial medication) was
recorded. Clinical examination, including axillary temper-
ature recording, staining of serial thick and thin films, was
performed on days 0, 1, 2, 3, 7, 14, and 28. Giemsa-
stained thick and thin films were read by a skilled micro-
scopist. Asexual- and sexual-stage parasites were counted,
and counts expressed per 200 white blood cells. Parasitae-
mia was calculated on the basis of a white blood cell count
of 8,000/µl. Thick-film examinations were considered toMalaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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be negative if no parasite was found in 100× high-power
fields. Blood was blotted onto filter paper at various time-
points during follow-up and stored at 4°C for DNA
extraction. Haemoglobin concentration was measured on
days 0 and 28 (HemoCue©, Anglholm, Sweden).
The primary end point was therapeutic response, based on
parasitological and clinical cure by day 28, according to
the 2001 WHO protocol [16]. Therapeutic response was
classified as "treatment failure" (TF; clinical deterioration
due to P. vivax illness requiring hospitalization, with par-
asitaemia and axillary temperature ≥ 37.5°C any time
between days 3 and 28, or parasitaemia on any day
between days 7 and 28, regardless of clinical conditions)
or "adequate clinical and parasitological response"
(ACPR; absence of parasitaemia on day 28 without the cri-
teria for TF previously being met). Patients with treatment
failure were treated with artesunate (4 mg/kg on days 0, 1,
and 2) plus amodiaquine (10 mg/kg on days 0, 1, and 2);
however, their response to repeat therapy was not
assessed.
Molecular genotyping techniques were used to distin-
guish recrudescences from reinfections for patients with
treatment failure after day 7. Briefly, blood samples col-
lected on the day of enrolment, on day 1 and on the day
of treatment failure were analysed by sequencing for pol-
ymorphisms in the genes for circumsporozoïte protein
(pvcsp) [17] and merozoite surface protein-3 (pvmsp3)
[18] and for six different microsatellite markers [19,20]
(Table 1). Microsatellite PCR products were size-geno-
typed by using a standard-size Genescan 500 LIZ on an
ABI Prism 3730XL. The genotyping patterns on the day of
failure were compared with those at treatment initiation
and on day 1. An outcome was defined as recrudescence if
all alleles present at the time of failure were present at the
time of treatment initiation or on day 1, and defined as a
reinfection otherwise.
The secondary end points were (i) fever clearance time,
defined as the time (days) from initiation of treatment to
the end of fever (i.e., patient remaining afebrile, based on
reported history, with an axillary temperature of <37.5°C
on a given day of follow-up); (ii) parasite clearance time,
defined as the time (days) from the initiation of treatment
to parasite clearance (defined as the moment when para-
site counts fell below the detection threshold for micros-
copy) and (iii) haematological recovery, defined as being
cured on day 28, with a haemoglobin level greater than
that on day 0.
DNA extraction, pvdhfr/pvdhps amplication and 
sequencing
DNA was extracted from blood spots with Instagene®
Matrix resin (BioRad©, Marnes la Coquette, France),
according to the manufacturer's instructions. Parasite spe-
cies were confirmed by real-time PCR, using species-spe-
cific primers previously described by de Monbrison [21],
with a protocol adapted for the RotorGene® 3000 thermo-
cycler (Corbett Life Science®, Sydney, Australia).
Plasmodium vivax isolates were genotyped for the pvdhfr
and pvdhps genes. DNA was amplified by semi-nested PCR
for pvdhfr gene amplification or by nested PCR for pvdhps,
using gene-specific primers [22,23]. PCR products were
purified, using polyacrylamide P-100 Gel (Bio-Gel P-100,
BioRad®, Marnes-la-Coquette, France), by 96-well plate
filtration (Millipore®, St. Quentin en Yvelines, France).
Sequencing reactions were performed using ABI PRISM
BigDye Terminator cycle sequencing ready reactions kit
Table 1: Primer sequences of the microsatellite markers used for differentiating recrudescences from reinfections in paired samples 
from enrolled patients with treatment failure after day 7.
Micro satellite markers Motif External PCR Internal PCR Label
14.185§ AT F: TGCAGATATGCTGTCGAAT F: GCAGTTGTTGCAGATTGAGC 6FAM
R: GGGAAAAACTTGGTCACAC R: TAAGGCGTGCACGTTATCAT
8.332§ AT F: TGAAGCAATATAGCGATGAC F: CCTCGATGGTGATGTGATGA HEX
R: CGGTGTAGTGTGGTACAATG R: GTATAACATGGCACCCGACCT
6.34§ AC F: CCCAATTAAGTGCAAATCA F: TGAGCGCTTTAAGCTTCTGC 6FAM
R: CATGTAAAGAGGCACATGG R: CAAAAATGAATCGTGGCACA
2.21§ AC F: GGCAGGAACGTAGAGGAG F: CCATCTGCTCAAATCCGAAG 6FAM
R: GGCTTGTTCATTTTGAGGTA R: GGCTCCTCCCTGTCTCTGTAG
AY391734# CA F: TACCCCAGCCTTATCTCTC F: TTTTCCCTTCGGAAAAACG 6FAM
R: AAATGCACAGACACTACGC R: ACGACCATCACCTGCCATAG
AY391740# AC F: ATTTGTGTATGCCTTGTGTT F: GTTTACCAGGCCCAATTCAC HEX
R: GTGAGGGTGTCTATCCGTA R: GTTCACACGGGCGTATACAT
§ microsatellites sequences described by Imwong et al, 2006 [20]
# microsatellites sequences described by Leclerc et al, 2004 [19]
Primers sequences were designed by primer3 software [39]
F: forward primer
R: reverse primerMalaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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and run on a 3730 xl Genetic Analyzer (Applied Biosys-
tems, Courtaboeuf, France). Electrophoregrams were visu-
alized and analysed with CEQ™ 2000 Genetic Analysis
System software (Beckman Coulter™). Amino-acid
sequences were compared with wild-type sequences (Gen-
Bank accession no. X98123 for pvdhfr and Genbank acces-
sion no. AY186730 for pvdhps), using BioEdit Sequence
Alignment Editor software [24]. Parasites with mixed alle-
les (both wild-type and mutant alleles present) were con-
sidered to be mutant. A second PCR product was
sequenced for confirmation if a new point mutation was
observed.
Nucleotide sequence accession number
The complete sequences of the alleles identified has been
submitted to GenBank and assigned accession numbers
EU168419 to EU168431 for pvdhfr  and EU176992 to
EU177003 for pvdhps.
Statistical analysis
Data were input into EpiInfo 6.04© software (Centers for
Disease Control and Prevention, Atlanta, Georgia, United
States), checked and analysed, using MedCalc© software
version 9.1.0.1 (MedCalc Software, Broekstraat 52, 9030
Mariakerke, Belgium) and Comprehensive meta-analysis
software version 2 (Biostat, Englewood, NJ 07631, USA).
An intention-to-treat analysis of treatment outcome was
carried out. Frequencies were compared using chi-squared
tests, and continuous variables were compared using Stu-
dent's t-tests or Mann-Whitney U-tests, as appropriate. All
reported p-values are for two-tailed tests and were consid-
ered statistically significant if less than 0.05.
Results
Prevalence of P. vivax infections
From January to October 2006 and March to July 2007,
8,363 patients were screened by using RDT. Among these
patients, the global prevalence of P. vivax infections was
estimated at 6.3% (135 cases) of all malaria infections by
microscopy. Considerable heterogeneity was observed
between the different study areas and prevalence ranged
from zero in Andapa to 17.5% in Tsiroanomandidy (Fig-
ure 1).
Analysis of the pvdhfr and pvdhps genes
159 P. vivax samples, corresponding to the 135 cases com-
pleted with 24 collected in the same conditions, were
sequenced on pvdhfr/pvdhps genes (Figure 1). A large pro-
portion of these samples (71%, 113/159) had at least one
mutation on the pvdhfr gene; this proportion ranged from
18% in Ejeda (2/11) to 100% in Ihosy and Farafangana
(1/1). These samples displayed non-synonymous muta-
tions at six residues, including four mutations known to
be responsible for pyrimethamine resistance (P33L,
C49R, S58R and S117N) and two previously unknown
mutations (P21S and N130K). The most prevalent
mutant-type alleles were S58R (58%) and S117N
(63.5%), particularly for study sites on the western side of
Madagascar. The mutant P33L allele, which has been
reported to be specific to Madagascar, was found in only
6% of isolates and was not restricted to any particular
area. The fourth mutation, C49R, was present in 3% of the
isolates and was limited to Maevatanana. The two new
non-synonymous mutations, P21S and N130K, were
identified in two and 50 isolates, respectively, at only two
sites (Miandrivazo and Tsiroanomandidy). An additional
synonymous mutation was detected at amino-acid 15
(gca → gcg) in 69 samples (43%). No variation in the
number of repeats was observed in the polymorphic
region between nucleotides 262 and 309 [25].
Non-synonymous mutations were found at two residues
of the pvdhps gene, in 25 of the 159 isolates: 24 samples
(15%) displayed the A383G mutant allele and one sample
(0.6%) the C422R mutant allele. No mutant alleles were
found at southern sites and such alleles were surprisingly
rare in Miandrivazo (3%), despite 83% of the isolates
from this site having mutant alleles of the pvdhfr gene.
Based on the pvdhps  tandem repeat region located
between amino-acid residues 603 to 658 of the reference
sequence, nine different genotypes, including the refer-
ence genotype, were identified. All the A383G mutant-
type isolates were from the same genotype. These changes
and the corresponding positions of mutations in pvdhfr
and pvdhps are shown in Table 2.
In total, 15 different genotypes were identified, as pre-
sented in Table 3, including wild-type and single, double
or triple mutant-types in for pvdhfr and the wild-type or
single mutants for pvdhps. Only 27.7% of the 159 isolates
sequenced were wild-type for both genes, and all but two
of the parasites with mutant genotypes for pvdhps (98.7%)
also had mutant genotypes for pvdhfr. Four single mutant
allele genotypes were observed for pvdhfr, but none of
these genotypes was ever associated with mutation in the
pvdhps gene. In the double-mutant genotype, the 130K
mutation was combined with 33L or 117N mutations in
the pvdhfr gene, in the absence of mutation in the pvdhps
gene. The pvdhfr 58R/117N double mutant accounted for
25.8% of isolates, 10.1% of which also had the A383G
mutation in the pvdhps gene. Finally, two triple-mutant
pvdhfr genotypes were observed, with and without muta-
tions in the pvdhps gene. The 49R/58R/117N genotype was
found only in Maevatanana, whereas the 58R/117N/130K
genotype was found mostly in Miandrivazo and Tsiroano-
mandidy.Malaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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Map of Madagascar showing the distribution of P. vivax isolates from each study area Figure 1
Map of Madagascar showing the distribution of P. vivax isolates from each study area.Malaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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Clinical and parasitological response to SP
Clinical and parasitological monitoring was complete up
to day 28 for 15 of the 16 patients enrolled in the clinical
study of SP efficacy. Nine of these 16 patients were male
Table 2: Frequency distribution of mutant-type alleles for DHFR and DHPS domains in 159 Malagasy isolates collected from 7 sites in 
2006–2007
P. vivax dhfr polymorphism P. vivax dhps polymorphism
Sampling site No. of 
isolates
No. of 
mutant 
isolates 
(%)
Amino-acid residue No. of 
mutant 
isolates 
(%)
Amino-acid residue
P21S P33L C49R S58R S117N N130K A383G C422R
South Ejeda 11 2 (18) - 1 - 1 1 - 0 (0) 0 0
Ihosy 1 1 (100) - - - - 1 - 0 (0) 0 0
West Miandriva
zo
60 50 (83) 1 1 - 43 47 44 2 (3) 1 1
Maevatana
na
22 14 (64) - 2 5 12 12 - 8 (36) 8 0
Central 
Highlands
Tdd 59 42 (71) 1 4 - 33 37 6 11 (19) 11 0
Moraman
ga
5 3 (60) - 1 - 2 2 - 3 (60) 3 0
East Farafangan
a
1 1  ( 1 0 0 ) --- 1 1 -1  ( 1 0 0 )1 0
Total 159 113 (71) 2 (1.3) 9 (5.7) 5 (3.1) 92 (57.9) 101 (63.5) 50 (31.4) 25 (16) 24 (15) 1 (0.6)
Residues displaying new mutations are indicated in bold typeface
Tdd: Tsiroanomandidy
Table 3: Frequency distribution of pvdhfr/pvdhps genotypes in 159 Malagasy isolates collected from 7 sites in 2006–2007
Sampling sites
dhfr alleles dhps alleles South West Central Highlands East Total isolates 
(frequency %)
Ejeda Ihosy Maevatanana Miandrivazo Tdd Moramanga Farafangana
No mutation
Wild-type Wild-type 9 - 7 10 17 1 - 44 (27.7)
383G - - 1 - - 1 - 2 (1.3)
Single mutant
21S Wild-type - - - 1 1 - - 2 (1.3)
33L Wild-type 1 - 2 - 4 1 - 8 (5.0)
117N Wild-type - 1 - 3 3 - - 7 (4.4)
130K Wild-type - - - 1 - - - 1 (0.6)
Double mutant
33L + 130K Wild-type - - - 1 - - - 1 (0.6)
117N + 130K Wild-type - - - 1 1 - - 2 (1.3)
58R + 117N Wild-type 1 - 4 2 18 - - 25 (15.7)
383G - - 3 - 10 2 1 16 (10.1)
Triple mutant
49R + 58R + 117N Wild-type - - 1 - - - - 1 (0.6)
383G - - 4 - - - - 4 (2.5)
Wild-type - - - 39 4 - - 43 (27.0)
58R + 117N + 130K 422R - - - 1 - - - 1 (0.6)
383G - - - 1 1 - - 2 (1.3)Malaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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and seven were female (43.4%). They were aged from
nine months to 42 years (median 7.5 years), and had a
median weight of 16.5 kg (range 7.5 to 52.5). Fifteen
patients (93.8%) had suffered fever during the 48 hours
immediately preceding enrolment and one declared hav-
ing taken antimalarial drugs (tetracycline). Neither micro-
scopy nor real-time PCR showed mixed infections (P.
vivax with other species). The geometric mean of asexual
parasite count was 3,353 parasites/µL (range 500 to
21,500) at baseline. None of the patients had detectable
gametocytes on microscopy at day 0 or during follow-up.
Mean haemoglobin concentration was 7.5 g/dL on day 0,
and the mean increase in haemoglobin concentration
observed on day 28 was 1.3 g/dL. Eleven patients success-
fully cleared P. vivax parasitaemia after SP treatment,
whereas four patients presented a reoccurrence of parasi-
taemia on days 14, 21 or 28. The final classification of the
recrudescent patients after adjustment by genotyping is
shown in Table 4. The treatment failure rate at day 28 by
intention-to-treat analysis was also estimated to 25%
(95% CI: 8–50) and after adjustment by genotyping to
19% (95% CI: 5–43). Mean fever clearance time was cal-
culated as 1.2 ± 0.7 days and, parasite clearance time was
calculated as 1.3 ± 0.9 days.
pvdhfr/pvdhps genotypes and clinical response to SP
No significant differences were observed between recru-
descent and non-recrudescent patients in terms of sex
ratio, mean temperature at day 0, mean age, initial mean
parasitaemia, haemoglobin concentration and mean
number of mutations in pvdhfr/pvdhps genes (Table 5).
The pvdhfr/pvdhps genotype and therapeutic response of
each isolate evaluated are listed in Table 6. Three of the
four patients carrying the pvdhfr/pvdhps triple-mutant gen-
otype (58R/117N, 383G) displayed ACPRs. The remain-
ing patient was classified treatment failure at day 28.
Considering the pvdhfr double mutant 58R/117N geno-
type, all 3 patients displaying treatment failure and 6 over
the 11 displaying ACPRs carried it, providing an odd ratio
for TF of 8.27 with a wide 95% CI of 0.35–197.6. The
molecular/therapeutic outcome relationship can't be
clearly depicted from these data.
Discussion
This study highlights the real burden of P. vivax infections
by updating prevalence data in eight sites throughout
Madagascar. Despite the likely underestimation of the
prevalence of P. vivax due to the use of the RDT for malaria
screening [2], this study confirms, however, that P. vivax is
the second prevalent species in malaria infections after P.
falciparum. The highest prevalence of Plasmodium vivax
infections were found in the western side of Madagascar,
certainly because of the predominance of ethnic groups of
Indo-Asian and Middle Eastern origin, who carry the
Duffy antigen [26].
SP resistance and related single nucleotide polymor-
phisms (SNPs) in the pvdhfr and pvdhps genes were ana-
lysed in P. vivax samples from seven sites representative of
the four major epidemiological strata for malaria. The two
genes were screened by sequencing, to identify possible
new mutations. The P. vivax pvdhfr gene is known to be
Table 4: Paired analysis of pvcsp, pvmsp3 and microsatellite markers sequences used for differentiating recrudescences from 
reinfections for the four patients with a reoccurrence of parasitemia (Tsiroanomandidy, Madagascar, 2006).
Allele sizes of microsatellites markers (bp) Genotypes in
Patient Day 6.34 L34 2.21 8.332 14.185 L40 pvcsp gene pvmsp3 gene Final classification
TDD062079 0 221/225 108 196 217 89/91 97 VK210 A Recrudescence
1 221/225 108 196 217 91 97 VK210 A
14 225 108 196 217 91 97 VK210 A
TDD06viv12 0 219 108/110 196 222 na 97 VK210 na Recrudescence
1 219 108/110 196 222 na 97 VK210 na
28 219 110 196 222 na 97 VK210 na
TDD06viv15 0 225 110 196 na 98 97 VK210 na Reinfection or Relapse
1 230 104 205 na 93 97 VK210 na
21 225 108 196 na 91 97 VK210 na
TDD06viv20 0 230 108 198 na 91 97 VK210 A Recrudescence
1 230 108 198 na 91 97 VK210 A
14 230 108 198 na 91 97 VK210 A
na: not available
Two infections (TDD062079 and TDD06viv12) were polyclonal as indicated by microsatellite markers analysis.
pvcsp sequences were classified as VK210 or VK247 types as described [17]; after DNA sequences alignment, no SNP was observed between day 0, 
1 and the day of reoccurent parasitemia.
pvmsp3 sequences were classified into types A (1900 bp), B (1300 bp) or C (1100 bp) as described [40]; after DNA sequences alignment, one SNP 
was observed between TDD062079 at day 0 and the sequences obtained from both days 1 and 14. No differences were observed between 
TDD06viv20 sequences.Malaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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highly diverse, supporting the use of such an approach
[27]. A very high proportion of mutant-type isolates
(72.2%) and diverse alleles were identified in these iso-
lates, with 15 different mutant-type alleles observed if
both pvdhfr and pvdhps gene mutations were taken into
account. This is the first time that mutations at positions
implicated in SP resistance have been described in P. vivax
isolates from Madagascar.
Only two substitutions were identified in pvdhps, whereas
six non-synonymous mutations, including four that have
already been described, were found in pvdhfr. Mutations
in these two genes do not play identical roles in the emer-
gence of SP-resistance. Similar observations have been
made for P. falciparum [28,29]. Mutations seem occurring
first in pfdhfr gene, then after in pfdhps gene when most of
the parasites in the population have double- or triple-
mutant alleles of the dhfr gene [22].
Mutations in pvdhfr, including 58R and 117N, have been
implicated in pyrimethamine resistance. The 58R allele
was found in 58% of all P. vivax isolates, in combination
with 117N, which was found alone or in combination
with other mutations in 63.5% of all isolates. Studies in
vitro have shown that the mutation of a single base, lead-
ing to the replacement of a serine by an asparagine residue
at codon 117, increases the IC50 value of pyrimethamine
by more than 80 times. The combination of this mutation
Table 5: Demographic, clinical and parasitological characteristics of baseline isolates from recrudescent and non-recrudescent patients 
(Tsiroanomandidy, Madagascar, 2006).
Patients
Recrudescent Non-Recrudescent P
No Value CI95% No Value CI95%
Patient charasteristics
No of males/No of females 3 3/0 - 11 4/7 -
Age (years), mean 3 5.3 0 – 15.6 11 14.7 5.3–24.0 NS
Temperature (°C), mean 3 38.8 35.8–41.9 11 38.0 37.6–38.4 NS
Hematology
Hemoglobin concentration (g/dL), mean 3 6.8 5.5 – 8.1 11 7,5 5.1–9.9 NS
Isolates at the baseline
Parasitemia (parasites/µL), geometric mean 3 3434 361 – 32627 11 3307 1603–6823 NS
Mean number of mutations in dhfr/dhps genes 3 2.3 1.6–3 11 1.4 0.6–2.2 NS
One patient presenting a P. falciparum infection and the one presenting a P. vivax reinfection (or relapse, as indicated by genotyping analysis) were 
excluded from the non-recrudescent patients group.
Table 6: The pvdhfr/pvdhps genotypes and therapeutic responses of 15 patients from Tsiroanomandidy (Madagascar, 2006) treated 
with sulphadoxine-pyrimethamine for P. vivax infections
Sequence polymorphism in
Patient pvdhfr Pvdhps No. of mutations in the 2 genes Therapeutic responseb
Trial no. Age (Years) 33 58 117 383
VIV7 2 P S S A 0 ACPR
60446 2.5 P S S A 0 ACPR
VIV14 7 L SS A 1 A C P R
VIV18 13 P S S A 0 ACPR
60756 42 P S S A 0 ACPR
VIV3 12 P RN G 3 ACPR
VIV8 34 P S N A1 A C P R
VIV20 9 P RN A2 T F
62298 5 P RN A2 A C P R
60250 6 P RN A2 A C P R
60149 8 P RN G 3 ACPR
VIV4 30 P RN G 3 ACPR
VIV12 6 P RN G 3T F
62079 0.8 P RN A2 T F
VIV15 2 P RN A 2 Reinfection or relapseMalaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
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with the replacement of a serine by an arginine residue at
codon 58 generates an enzyme more than 400 times more
resistant to pyrimethamine than the wild-type enzyme
[30,31]. The 57L/58R/117N, triple mutant previously
observed in Thailand [14] and associated with low levels
of parasite clearance was not found. No parasites of the
57L/58R/61M/117T quadruple mutant type, associated
with a high risk of SP treatment failure, were also not
found.
Two new mutations were found at codons 21 and 130 in
the pvdhfr gene. The mutation at codon 130 accounted for
31.4% of the isolates. This mutation, present mostly at
Miandrivazo (67% of isolates), was strongly associated
with the 58R/117N double mutant. The P33L substitution
accounted for only 6% of the isolates. This mutation was
previously found to be associated with isolates of Como-
rian or Malagasy origin [14,25]. One of the unique fea-
tures of the pvdhfr gene of P. vivax is the presence of a
tandem repeat between amino-acid residues 70 and 110.
Size polymorphism has been reported in this region
[22,32], but no variation was observed in this study.
It was impossible to assess the impact of the new N130K
mutation based on clinical data, because only the 58R/
117N double mutant was observed in isolates from the
patients enrolled in the clinical trial of SP efficacy, includ-
ing the isolate with the A383G mutation in pvdhps. The
use of yeast constructs might facilitate interpretation of
the role of this mutation in resistance [33].
Because of the absence of a genotyping consensus proto-
col for P. vivax to differentiate recrudescence from reinfec-
tion, the use of a combination of different genes such as
pvama1, pvmsp1, pvmsp3 or microsatellite markers in
paired analysis seems to be the safest available method. In
this study, pvcsp and pvmsp3 genes sequencing and six dif-
ferent microsatellite markers were used on samples from
day 0, day 1 and day of reoccurrence. The use of microsat-
ellite markers seems to be useful as more polyclonal infec-
tions could be detected. Obvioulsy, the main limitation of
this protocol was the well-recognized impossibility to
prove that a P. vivax reoccurrence was a recrudescence, a
relapse or a reinfection.
No significant association between pvdhfr/pvdhps  poly-
morphisms and SP-treatment outcome was found, but all
recrudescent patients were pvdhfr double-mutant carrier.
This result strongly suggests that infection due to the pvd-
hfr 58R/117N double mutant is necessary but not suffi-
cient for SP treatment failure to occur. The treatment
outcome is likely to be favourable if the parasite has a
wild-type genotype, but in parasites with mutations, out-
come depends on the alleles present at the pvdhfr and
pvdhps loci and the individual response of the patient [12].
Currently, it is well known that beside parasite factors,
host factors such as nutritional status, immune response
and rates of drug metabolism are involved in determining
treatment outcome.
Surprisingly, almost 72.3% of the tested P. vivax isolates
had mutations in the pvdhfr and/or pvdhps genes, despite
SP never having been recommended as a first-line treat-
ment for malaria, but only as a second-line treatment
from 1998 to 2005. ACT is now recommended for the
treatment of uncomplicated malaria regardless of the
causal  Plasmodium  species. Nevertheless, self-treatment
remains frequent in Madagascar since unpublished study
has shown that three quarters of all febrile patients attend-
ing government health facilities have already used chloro-
quine in 67.6% of cases, cotrimoxazole
(sulphamethoxazol/trimethoprim) in 23.4% and SP in
9.4% of cases. Cotrimoxazole is the drug most widely
used to treat diarrhoea as well as respiratory infections
[34]. Asymptomatic P. vivax infections and treatment with
trimethoprim are probably common, resulting in the
exposure of parasites to this drug. Mutations in the pvdhfr
and pvdhps genes may reflect overall antifolate drug pres-
sure in Madagascar.
Previous studies have shown that dhfr  mutant P. falci-
parum isolates were extremely rare [35], with only one
case of infection with the 108N mutant reported in the
south of Madagascar. Based the observations for P. vivax
isolates, data for P. falciparum genotypes should be
updated.
Conclusion
SP has been recommended for intermittent preventive
treatment during pregnancy since 2005 in Madagascar.
The regional office of the WHO for Africa currently recom-
mends IPTp with SP in countries with a parasitological
failure rate of less than 50% [36]. With a frequency of TF
estimated at 19% and a prevalence of up to 17.5% of all
malaria cases, P. vivax infections remains a public health
problem in Madagascar and there is no doubt that SP will
not be completely effective in IPTp strategy [37,38]. The
extensive use of SP will increase the drug selection pres-
sure on the parasite and favour the spread of resistance. As
a result, this study highlights (i) that genotyping in the
pvdhfr gene remains a useful tool to monitor the emer-
gence and the spread of P. vivax SP-resistant in order to
improve the national antimalarial drug policy, (ii) the
issue of using SP as a monotherapy for IPT of pregnant
women or children.
Authors' contributions
CBa performed laboratory work and wrote the manu-
script. MT and CBo carried out sequencing and gave con-
structive advice. AR, LR and RR performed the field work.Malaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
Page 10 of 11
(page number not for citation purposes)
MJ performed laboratory work. SP helped with the writing
of the manuscript and gave constructive advice. DM was
involved in all stages of this study.
Acknowledgements
We thank the patients and healthcare workers involved in the national net-
work for the surveillance of malaria resistance in Madagascar (Réseau 
d'Etude de la Résistance, RER) from which these samples were obtained, 
and the staff of the Ministry of Health of Madagascar for their collaboration. 
We thank Hanitra Ranaivosoa, Didier Ralaizandry, Daimondra Raveloarise-
heno and Vony Rabekotorina for helping with field work.
This work was supported by grant from the French Ministry of Foreign 
Affairs, FSP/RAI 2001-168 project. Sample collection was funded by the 
Global Fund project for Madagascar round 3 (Community Action to Roll 
Back Malaria, Grant number: MDG-304-G05-M).
CBa is a PhD student supported by the Fondation Jeunesse Internationale 
(Fondation de France), BioMérieux "Prix BioMérieux infectiologie 2006", 
Association des Internes et Anciens Internes en Pharmacie des Hôpitaux de 
Lyon "Prix R. Rizard", and the Hospices Civils de Lyon.
References
1. Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden
of Plasmodium vivax malaria.  Am J Trop Med Hyg 2001, 64(1-2
Suppl):97-106.
2. Ratsimbasoa A, Randriamanantena A, Raherinjafy R, Rasoarilalao N,
Menard D: Which malaria rapid test for Madagascar? Field
and laboratory evaluation of three tests and expert micros-
copy of samples from suspected malaria patients in Mada-
gascar.  Am J Trop Med Hyg 2007, 76(3):481-485.
3. Robert V, Le Goff G, Andrianaivolambo L, Randimby FM, Domarle O,
Randrianarivelojosia M, Raharimanga V, Raveloson A, Ravaonjanahary
C, Ariey F: Moderate transmission but high prevalence of
malaria in Madagascar.  Int J Parasitol 2006, 36(12):1273-1281.
4. Enquête auprès des Ménages.   Institut National de la Statistique
de Madagascar; 2002:71-83. 
5. Jeremiah M SA: Mortalité des enfants de moins de 5 ans à
Madagascar.  Enquête Démographique et de la Santé III à Madagascar
2004:191-201.
6. UNICEF: Multiple Indicator Cluster Survey (MICS).  2000.
7. Rabarijaona LP RT Ranaivo LH, Raharimalala LA, Rakotomanana F,
Rakotondraibe EM, Ramarosandratana B, Rakotoson JD, Rakoton-
janabelo LA, Tafangy PB: Paludisme sur les hautes terres cent-
rales de Madagascar: stratégies de lutte.  Méd Trop 2006,
66(5):504-512.
8. Randrianasolo L, Randriamanantena A, Ranarivelo L, Ratsimbasoa A,
Domarle O, Randrianarivelojosia M: Monitoring susceptibility to
sulfadoxine-pyrimethamine among cases of uncomplicated,
Plasmodium falciparum malaria in Saharevo, Madagascar.
Ann Trop Med Parasitol 2004, 98(6):551-554.
9. Randrianarivelojosia M, Ariey F, Raharimalala LA, Parzy D, Rogier C,
Jambou R: Current absence of pyrimethamine resistance of
Plasmodium falciparum in Madagascar.  Trans R Soc Trop Med
Hyg 2002, 96(5):557-559.
10. Randrianarivelojosia M, Harisoa JL, Rabarijaona LP, Raharimalala LA,
Ranaivo L, Pietra V, Duchemin JB, Rakotomanana F, Robert V, Mau-
clere P, Ariey F: In vitro sensitivity of Plasmodium falciparum
to amodiaquine compared with other major antimalarials in
Madagascar.  Parassitologia 2002, 44(3-4):141-147.
11. Rason MA, Ariey F, Rafidimanantsoa L, Andrianantenaina BH, Sahon-
dra Harisoa JL, Randrianarivelojosia M: Monitoring the drug-sen-
sitivity of Plasmodium falciparum in coastal towns in
Madagascar by use of in vitro chemosensitivity and mutation
detection tests.  Parasite 2002, 9(3):247-253.
12. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH:
Antifolates can have a role in the treatment of Plasmodium
vivax.  Trends Parasitol 2007, 23(5):213-222.
13. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK:
Sequence variations in the Plasmodium vivax dihydrofolate
reductase-thymidylate synthase gene and their relationship
with pyrimethamine resistance.  Mol Biochem Parasitol 1998,
92(2):265-273.
14. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J,
White NJ, Snounou G: Association of genetic mutations in Plas-
modium vivax dhfr with resistance to sulfadoxine-pyrimeth-
amine: geographical and clinical correlates.  Antimicrob Agents
Chemother 2001, 45(11):3122-3127.
15. Udomsangpetch R, Kaneko O, Chotivanich K, Sattabongkot J: Culti-
vation of Plasmodium vivax.  Trends Parasitol 2008, 24(2):85-88.
16. WHO: Monitoring antimalarial drug resistance, Report of a
WHO consultation.  Geneva, Switzerland , World Health Organi-
zation; 2002. 
17. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F,
Looareesuwan S, White NJ, Snounou G: Practical PCR genotyp-
ing protocols for Plasmodium vivax using Pvcs and Pvmsp1.
Malar J 2005, 4(1):20.
18. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP: Polymor-
phism at the merozoite surface protein-3alpha locus of Plas-
modium vivax: global and local diversity.  Am J Trop Med Hyg
1999, 61(4):518-525.
19. Leclerc MC, Durand P, Gauthier C, Patot S, Billotte N, Menegon M,
Severini C, Ayala FJ, Renaud F: Meager genetic variability of the
human malaria agent Plasmodium vivax.  Proc Natl Acad Sci U S
A 2004, 101(40):14455-14460.
20. Imwong M, Sudimack D, Pukrittayakamee S, Osorio L, Carlton JM,
Day NP, White NJ, Anderson TJ: Microsatellite variation, repeat
array length, and population history of Plasmodium vivax.
Mol Biol Evol 2006, 23(5):1016-1018.
21. de Monbrison F, Angei C, Staal A, Kaiser K, Picot S: Simultaneous
identification of the four human Plasmodium species and
quantification of Plasmodium DNA load in human blood by
real-time polymerase chain reaction.  Trans R Soc Trop Med Hyg
2003, 97(4):387-390.
22. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP,
Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G: Novel
point mutations in the dihydrofolate reductase gene of Plas-
modium vivax: evidence for sequential selection by drug
pressure.  Antimicrob Agents Chemother 2003, 47(5):1514-1521.
23. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q:
Sulfadoxine resistance in Plasmodium vivax is associated
with a specific amino acid in dihydropteroate synthase at the
putative sulfadoxine-binding site.  Antimicrob Agents Chemother
2004, 48(6):2214-2222.
24. Hall TA: BioEdit: a user-friendly biological sequence align-
ment editor and analysis program for Windows 95/98/NT.
Nucl Acids Symp Ser 1999:95-98.
25. Eldin de Pecoulas P, Basco LK, Tahar R, Ouatas T, Mazabraud A:
Analysis of the Plasmodium vivax dihydrofolate reductase-
thymidylate synthase gene sequence.  Gene 1998,
211(1):177-185.
26. Hurles ME, Sykes BC, Jobling MA, Forster P: The dual origin of the
Malagasy in Island Southeast Asia and East Africa: evidence
from maternal and paternal lineages.  Am J Hum Genet 2005,
76(5):894-901.
27. Hastings MD, Maguire JD, Bangs MJ, Zimmerman PA, Reeder JC, Baird
JK, Sibley CH: Novel Plasmodium vivax dhfr alleles from the
Indonesian Archipelago and Papua New Guinea: association
with pyrimethamine resistance determined by a Saccharo-
myces cerevisiae expression system.  Antimicrob Agents Chem-
other 2005, 49(2):733-740.
28. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Wat-
kins WM: Towards an understanding of the mechanism of
pyrimethamine-sulfadoxine resistance in Plasmodium falci-
parum: genotyping of dihydrofolate reductase and dihydrop-
teroate synthase of Kenyan parasites.  Antimicrob Agents
Chemother 2000, 44(4):991-996.
29. Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, Win-
stanley PA, Watkins WM: Molecular evidence of greater selec-
tive pressure for drug resistance exerted by the long-acting
antifolate Pyrimethamine/Sulfadoxine compared with the
shorter-acting chlorproguanil/dapsone on Kenyan Plasmo-
dium falciparum.  J Infect Dis 2000, 181(6):2023-2028.
30. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ,
Sibley CH, Baird JK: Dihydrofolate reductase mutations in Plas-
modium vivax from Indonesia and therapeutic response toPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2008, 7:35 http://www.malariajournal.com/content/7/1/35
Page 11 of 11
(page number not for citation purposes)
sulfadoxine plus pyrimethamine.  J Infect Dis 2004,
189(4):744-750.
31. Hastings MD, Sibley CH: Pyrimethamine and WR99210 exert
opposing selection on dihydrofolate reductase from Plasmo-
dium vivax.  Proc Natl Acad Sci U S A 2002, 99(20):13137-13141.
32. Kaur S, Prajapati SK, Kalyanaraman K, Mohmmed A, Joshi H, Chauhan
VS: Plasmodium vivax dihydrofolate reductase point muta-
tions from the Indian subcontinent.  Acta Trop 2006,
97(2):174-180.
33. Djapa LY, Basco LK, Zelikson R, Rosowsky A, Djaman JA, Yonkeu JN,
Bolotin-Fukuhara M, Mazabraud A: Antifolate screening using
yeast expressing Plasmodium vivax dihydrofolate reductase
and in vitro drug susceptibility assay for Plasmodium falci-
parum.  Mol Biochem Parasitol 2007, 156(1):89-92.
34. Randrianarivelojosia M RL Randriamanantena A, Jambou R: Chimi-
orésistance de Plasmodium falciparum sur les régions
cotières malgaches.  Méd Trop 2000, 60:243-249.
35. Randrianarivelojosia M RL Parzi D, Roux JF, Jambou R: DHFR and
Plasmodium falciparum resistance to antifolates: search for
other mutations in the Indian Ocean region.  Bull Soc Path Exot
1999, 92:282.
36. WHO: WHO Expert Comittee on Malaria.  Geneva, Switzer-
land , World Health Organization; 2000. 
37. Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, Hki-
rijaroen L, Looareesuwan S, White NJ: Effects of Plasmodium
vivax malaria in pregnancy.  Lancet 1999, 354(9178):546-549.
38. Singh N, Shukla MM, Sharma VP: Epidemiology of malaria in
pregnancy in central India.  Bull World Health Organ 1999,
77(7):567-572.
39. Rozen S, Skaletsky H: Primer3 on the WWW for general users
and for biologist programmers.  Methods Mol Biol 2000,
132:365-386.
40. Rayner JC, Corredor V, Feldman D, Ingravallo P, Iderabdullah F,
Galinski MR, Barnwell JW: Extensive polymorphism in the Plas-
modium vivax merozoite surface coat protein MSP-3alpha is
limited to specific domains.  Parasitology 2002, 125(Pt
5):393-405.